Charles River Laboratories International, Inc.
CRL NYSEHealthcare ★★★★★Latest Earnings
Date
Aug 5, 2026
ET
EPS Est.
2.74
EPS Actual
3.02
Revenue Est.
$977.2M
Revenue Actual
$1B
Next Earnings Report
Date
Nov 4, 2026 · Wed
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
2.97
Revenue Est.
$958.5M
Company Overview
Charles River Laboratories International, Inc. (ticker CRL) is listed on NYSE with a market cap of about $14.22B. Its next earnings report (FY2026 Q3) is expected on Nov 4, 2026 (ET), Pre-market, with consensus EPS of 2.97. In the last 15 reported quarters, EPS beat consensus estimates 15 times.
Actual EPS TrendRecently15Term · Feb 22, 2023 → Aug 5, 2026
Feb 22, 2023Range: 2.06 ~ 3.12Aug 5, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 5, 2026 | -- | 2.74 | 3.02 | $977.2M | $1B |
| May 7, 2026 | -- | 1.96 | 2.06 | $977.5M | $995.8M |
| Feb 18, 2026 | -- | 2.33 | 2.39 | $987M | $994.2M |
| Nov 5, 2025 | -- | 2.32 | 2.43 | $987.2M | $1B |
| Aug 6, 2025 | -- | 2.50 | Above forecast↑3.12 | $968.9M | $1.03B |
| May 7, 2025 | -- | 2.06 | 2.34 | $958.8M | $984.2M |
| Feb 19, 2025 | -- | 2.50 | 2.66 | $948.2M | $1B |
| Nov 6, 2024 | -- | 2.42 | 2.59 | $976M | $1.01B |
| Aug 7, 2024 | -- | 2.39 | Above forecast↑2.80 | $1.02B | $1.03B |
| May 9, 2024 | -- | 2.06 | 2.27 | $992.3M | $1.01B |
| Feb 14, 2024 | -- | 2.39 | 2.46 | $991.3M | $1.01B |
| Nov 8, 2023 | -- | 2.35 | Above forecast↑2.72 | $1B | $1.03B |
| Aug 9, 2023 | -- | 2.63 | 2.69 | $1.05B | $1.06B |
| May 11, 2023 | -- | 2.59 | 2.78 | $986.4M | $1.03B |
| Feb 22, 2023 | -- | 2.75 | 2.98 | $1.04B | $1.1B |
Original Filings (SEC)
10-Q2026-08-05 ↗
8-K2026-08-05 ↗
8-K2026-05-11 ↗
10-Q2026-05-07 ↗
8-K2026-05-07 ↗
8-K2026-02-25 ↗
8-K2026-02-18 ↗
10-K2026-02-18 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
